| SFC(n = 19) | FP(n = 17) | Placebo(n = 15) | |
| CD8+ T lymphocytes | |||
| Baseline mean | 191 (79) | 195 (69) | 187 (43) |
| Post-treatment mean | 107 (31) | 164 (67) | 201 (48) |
| Mean change from baseline | −84 (67) | −31 (47) | 14 (41) |
| Median change from baseline | −75 (−110 to −34) | −24 (−51 to −15) | 11 (−4 to 41.50) |
| p Value for mean change from baseline | <0.001 | 0.20 | 0.42 |
| CD68+ macrophages | |||
| Baseline mean | 102 (37) | 122 (49) | 135 (53) |
| Post-treatment mean | 74 (24) | 122 (49) | 136 (40) |
| Mean change from baseline | −29 (22) | 0 (33) | 2 (49) |
| Median change from baseline | −30 (−41 to −10) | −2 (−15 to 30) | 20 (−38 to 34) |
| p Value for mean change from baseline | 0.008 | 0.98 | 0.88 |
| Neutrophils | |||
| Baseline mean | 50 (19) | 53 (20) | 41 (26) |
| Post-treatment mean | 41 (19) | 67 (24) | 36 (21) |
| Mean change from baseline | −9 (18) | 14 (12) | −4 (15) |
| Median change from baseline | −11 (−19 to 0.5) | 18 (6 to 21) | −4 (−11 to 7.5) |
| p Value for mean change from baseline | 0.16 | 0.07 | 0.62 |
| Eosinophils | |||
| Baseline mean | 5 (5) | 9 (7) | 7 (4) |
| Post-treatment mean | 5 (4) | 8 (7) | 9 (5) |
| Mean change from baseline | −0.4 (5) | −1 (6) | 3 (7) |
| Median change from baseline | 0 (−3 to 3) | −1 (−2 to 3) | 1 (0.5 to 7) |
| p Value for mean change from baseline | 0.80 | 0.61 | 0.09 |
SFC, salmeterol xinafoate/fluticasone propionate; FP, fluticasone propionate.
Data expressed as mean (SD) or median (interquartile ranges).